FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027031567> ?p ?o ?g. }

• W2027031567 endingPage "385" @default.
• W2027031567 startingPage "378" @default.
• W2027031567 abstract "Most patients with acute myocardial infarction (AMI) are admitted to hospitals without percutaneous transluminal coronary angioplasty (PTCA) facilities or are initially managed in a prehospital mobile unit. Thrombolysis remains the most readily available reperfusion treatment in those settings, but the optimal subsequent strategy in those patients is unclear. If a mechanical recanalization is likely to be performed in an emergency, it is probably desirable that the patient receives abciximab, the glycoprotein IIb/IIIa antagonist with the strongest evidence of benefit for angioplasty in AMI.The aim of this trial is to compare the effects on clinical outcome and cost-effectiveness of 2 strategies after immediate treatment with abciximab and half-dose reteplase for ST-elevation AMI: to manage the patients conservatively (referring them for rescue PTCA only if needed) or to immediately send all patients for emergency coronary angioplasty.The Combined Abciximab RE-teplase Stent Study in Acute Myocardial Infarction (CARESS in AMI) is an open, prospective, randomized, multicenter clinical trial conducted in patients with high-risk ST-segment elevation AMI treated within 12 hours from symptom onset in hospitals without PTCA facilities or in a prehospital mobile intensive care unit. Apart from contraindications to thrombolysis, the main exclusion criteria are age > or =75 years and a past history of CABG surgery or a percutaneous coronary intervention procedure involving the infarct-related artery. Enrollment will be performed in hospitals without PTCA facilities or directly in the ambulance if a dedicated system is in place for prehospital diagnosis and treatment of AMI. Patients will receive half-dose reteplase and full-dose abciximab and will subsequently be randomized to conventional medical therapy (with referral for emergency rescue PTCA allowed in selected cases) or emergency angioplasty. The primary end point is the 30-day combined incidence of mortality, reinfarction, and refractory ischemia. In order to obtain a 95% power (2-sided) to detect a 42% reduction in the primary end point, 900 patients are required in each arm of the study. Secondary end points include the 1-year composite end point of mortality, reinfarction, refractory ischemia, and hospital readmission because of heart failure; resource use at 30 days and 1 year; and the incidence of inhospital stroke and bleeding complications in the 2 groups.Seventy-four patients have been randomized (as of March 10, 2004); results are expected in June 2005.This study will establish whether angioplasty must be started as soon as possible in all patients who receive combined pharmacologic reperfusion with the glycoprotein IIb/IIIa inhibitor abciximab and half-dose thrombolysis or whether it can be postponed or skipped in patients with signs of successful reperfusion, with obvious organizational advantages." @default.
• W2027031567 created "2016-06-24" @default.
• W2027031567 creator A5002902337 @default.
• W2027031567 creator A5003629502 @default.
• W2027031567 creator A5003831287 @default.
• W2027031567 creator A5007999411 @default.
• W2027031567 creator A5020343443 @default.
• W2027031567 creator A5022935861 @default.
• W2027031567 creator A5035216830 @default.
• W2027031567 creator A5036197968 @default.
• W2027031567 creator A5037858868 @default.
• W2027031567 creator A5049675934 @default.
• W2027031567 creator A5054614012 @default.
• W2027031567 creator A5065763434 @default.
• W2027031567 creator A5068281952 @default.
• W2027031567 creator A5071602214 @default.
• W2027031567 creator A5076374312 @default.
• W2027031567 creator A5076572784 @default.
• W2027031567 creator A5081617630 @default.
• W2027031567 creator A5083941254 @default.
• W2027031567 creator A5087166901 @default.
• W2027031567 creator A5089907464 @default.
• W2027031567 date "2004-09-01" @default.
• W2027031567 modified "2023-09-26" @default.
• W2027031567 title "Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI)" @default.
• W2027031567 cites W1485646988 @default.
• W2027031567 cites W1968120780 @default.
• W2027031567 cites W1972109636 @default.
• W2027031567 cites W2006556834 @default.
• W2027031567 cites W2006926412 @default.
• W2027031567 cites W2030341992 @default.
• W2027031567 cites W2032578967 @default.
• W2027031567 cites W2040393337 @default.
• W2027031567 cites W2051609274 @default.
• W2027031567 cites W2059289792 @default.
• W2027031567 cites W2060857631 @default.
• W2027031567 cites W2067329489 @default.
• W2027031567 cites W2098245131 @default.
• W2027031567 cites W2100879034 @default.
• W2027031567 cites W2105988283 @default.
• W2027031567 cites W2111977341 @default.
• W2027031567 cites W2122405823 @default.
• W2027031567 cites W2127419544 @default.
• W2027031567 cites W2128863498 @default.
• W2027031567 cites W2130165076 @default.
• W2027031567 cites W2130806602 @default.
• W2027031567 cites W2137036027 @default.
• W2027031567 cites W2142143365 @default.
• W2027031567 cites W2148173946 @default.
• W2027031567 cites W2148691829 @default.
• W2027031567 cites W2151363643 @default.
• W2027031567 cites W2159121887 @default.
• W2027031567 cites W2164749239 @default.
• W2027031567 cites W2333133657 @default.
• W2027031567 cites W4231815458 @default.
• W2027031567 doi "https://doi.org/10.1016/j.ahj.2004.03.038" @default.
• W2027031567 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15389222" @default.
• W2027031567 hasPublicationYear "2004" @default.
• W2027031567 type Work @default.
• W2027031567 sameAs 2027031567 @default.
• W2027031567 citedByCount "38" @default.
• W2027031567 countsByYear W20270315672012 @default.
• W2027031567 countsByYear W20270315672014 @default.
• W2027031567 countsByYear W20270315672015 @default.
• W2027031567 countsByYear W20270315672020 @default.
• W2027031567 crossrefType "journal-article" @default.
• W2027031567 hasAuthorship W2027031567A5002902337 @default.
• W2027031567 hasAuthorship W2027031567A5003629502 @default.
• W2027031567 hasAuthorship W2027031567A5003831287 @default.
• W2027031567 hasAuthorship W2027031567A5007999411 @default.
• W2027031567 hasAuthorship W2027031567A5020343443 @default.
• W2027031567 hasAuthorship W2027031567A5022935861 @default.
• W2027031567 hasAuthorship W2027031567A5035216830 @default.
• W2027031567 hasAuthorship W2027031567A5036197968 @default.
• W2027031567 hasAuthorship W2027031567A5037858868 @default.
• W2027031567 hasAuthorship W2027031567A5049675934 @default.
• W2027031567 hasAuthorship W2027031567A5054614012 @default.
• W2027031567 hasAuthorship W2027031567A5065763434 @default.
• W2027031567 hasAuthorship W2027031567A5068281952 @default.
• W2027031567 hasAuthorship W2027031567A5071602214 @default.
• W2027031567 hasAuthorship W2027031567A5076374312 @default.
• W2027031567 hasAuthorship W2027031567A5076572784 @default.
• W2027031567 hasAuthorship W2027031567A5081617630 @default.
• W2027031567 hasAuthorship W2027031567A5083941254 @default.
• W2027031567 hasAuthorship W2027031567A5087166901 @default.
• W2027031567 hasAuthorship W2027031567A5089907464 @default.
• W2027031567 hasConcept C126322002 @default.
• W2027031567 hasConcept C164705383 @default.
• W2027031567 hasConcept C2777698277 @default.
• W2027031567 hasConcept C2777871224 @default.
• W2027031567 hasConcept C2777995511 @default.
• W2027031567 hasConcept C2778583881 @default.
• W2027031567 hasConcept C2779581417 @default.
• W2027031567 hasConcept C2780326628 @default.
• W2027031567 hasConcept C2780400711 @default.
• W2027031567 hasConcept C2780790693 @default.
• W2027031567 hasConcept C500558357 @default.
• W2027031567 hasConcept C71924100 @default.

• next